Novo Nordisk's Wegovy cuts heart risk by 57% versus rival Lilly weight-loss drug in study

Novo Nordisk announced real-world study data indicating its weight-loss drug Wegovy reduced the risk of heart attack, stroke, or death by 57% more than Eli Lilly's tirzepatide-based rivals (Mounjaro/Zepbound) in overweight and obese patients with cardiovascular disease but without diabetes. This finding, while from a non-randomized comparison, suggests a potential differentiation in cardiovascular benefits among GLP-1s, which could significantly bolster Novo's competitive position and market share against Lilly in the rapidly expanding $150 billion weight-loss market, where it has recently faced increased competition.

Analysis

Novo Nordisk has presented real-world study data suggesting its weight-loss drug, Wegovy, demonstrates a 57% greater reduction in the risk of heart attack, stroke, or death compared to Eli Lilly's rival tirzepatide-based drugs, Mounjaro and Zepbound. The comparison focused on overweight and obese patients with cardiovascular disease but not diabetes. While this was a non-randomized, real-world study with a short average follow-up duration of approximately four months, the findings provide Novo Nordisk with a powerful argument for the clinical differentiation of its product. This data directly challenges the narrative of interchangeability among GLP-1 drugs and arrives at a critical juncture, as Novo has been losing U.S. market share to Zepbound and recently instituted a hiring freeze. Despite the study's limitations, including a low absolute number of adverse events (0.1% for Wegovy vs. 0.4% for tirzepatide), this evidence could significantly influence prescribing patterns and payer negotiations within the highly competitive weight-loss market, which is anticipated to reach $150 billion by the early 2030s. The news serves as a strong counterpoint to dampened growth expectations that recently led Denmark to lower its 2025 economic forecast.

Key Decisions for Investors

• This data represents a significant positive catalyst for Novo Nordisk (NVO), providing a key clinical differentiator that could help reclaim market share from Eli Lilly and support premium pricing power.
• For investors in Eli Lilly (LLY), these findings constitute a notable competitive headwind; it is crucial to monitor prescription volume data for any shifts in market share and for any formal response or counter-studies from the company.
• While the headline figure is compelling for Novo, investors should remain cognizant of the study's limitations, particularly its non-randomized design and short duration, as the initial market reaction may not fully account for the possibility of different outcomes in longer-term, more rigorous trials.